Lapatinib safe and efficacious as First-Line Therapy for ErbB2-Amplified Locally Advanced or Metastatic Breast Cancer

Lapatinib has demonstrated efficacy and was well tolerated as first-line therapy in ErbB2-amplified locally advanced or metastatic breast cancer.

ACT Biotech acquire kinase inhibitors from Bayer

ACT Biotech, a new oncology pharmaceutical company has acquired kinase inhibitor programs from Bayer, namely an anti-angiogenic receptor tyrosine kinase inhibitor entering Phase II clinical studies for colorectal cancer, a multi-mode kinase inhibitor in late preclinical stage testing and several preclinical stage programs in oncology.

Nexavar with dacarbazine improves survival in advanced melanoma

Results from a Phase II study show Nexavar (sorafenib), in combination with dacarbazine, improves progression-free survival (PFS) in patients with advanced melanoma

Crelux and ProQinase collaborate to provide off-the-shelf crystal-grade protein kinase portfolio

Crelux and ProQinase have formed a partnership to provide crystal-grade protein kinases and readily available kinase complex structures